{"name":"Fundación Pública Andaluza Progreso y Salud","slug":"fundaci-n-p-blica-andaluza-progreso-y-salud","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Cloxacilin","genericName":"Cloxacilin","slug":"cloxacilin","indication":"Other","status":"discontinued"},{"name":"Roflumilast alternated days","genericName":"Roflumilast alternated days","slug":"roflumilast-alternated-days","indication":"Other","status":"marketed"},{"name":"Subcutaneous glargine insulin","genericName":"Subcutaneous glargine insulin","slug":"subcutaneous-glargine-insulin","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Discontinuation antipsychotic treatment","genericName":"Discontinuation antipsychotic treatment","slug":"discontinuation-antipsychotic-treatment","indication":"Evaluation of antipsychotic discontinuation outcomes in schizophrenia or related psychotic disorders","status":"phase_3"},{"name":"Antipsychotic treatment","genericName":"Antipsychotic treatment","slug":"antipsychotic-treatment","indication":"Schizophrenia","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Hyperbaric bupivacaine+Morphine","genericName":"Hyperbaric bupivacaine+Morphine","slug":"hyperbaric-bupivacaine-morphine","indication":"Spinal anesthesia for surgical procedures","status":"marketed"},{"name":"Hyperbaric bupivacaine+Sufentanil","genericName":"Hyperbaric bupivacaine+Sufentanil","slug":"hyperbaric-bupivacaine-sufentanil","indication":"Spinal anesthesia for surgical procedures","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Amchafibrin","genericName":"Amchafibrin","slug":"amchafibrin","indication":"Contraception","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Regular insulin added to TPN bag","genericName":"Regular insulin added to TPN bag","slug":"regular-insulin-added-to-tpn-bag","indication":"Hyperglycemia management in patients receiving total parenteral nutrition (TPN)","status":"marketed"}]}],"pipeline":[{"name":"Discontinuation antipsychotic treatment","genericName":"Discontinuation antipsychotic treatment","slug":"discontinuation-antipsychotic-treatment","phase":"phase_3","mechanism":"This is a clinical trial protocol studying the effects of discontinuing antipsychotic medication in patients currently treated with antipsychotics.","indications":["Evaluation of antipsychotic discontinuation outcomes in schizophrenia or related psychotic disorders","Assessment of relapse risk and symptom recurrence following antipsychotic withdrawal"],"catalyst":""},{"name":"Amchafibrin","genericName":"Amchafibrin","slug":"amchafibrin","phase":"phase_3","mechanism":"Plasminogen","indications":["Contraception","Endometriosis","Female hypogonadism syndrome","Hemorrhaging in Hemophilia","Menorrhagia"],"catalyst":""},{"name":"Antipsychotic treatment","genericName":"Antipsychotic treatment","slug":"antipsychotic-treatment","phase":"phase_3","mechanism":"Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Bipolar disorder","Psychotic disorders"],"catalyst":""},{"name":"Cloxacilin","genericName":"Cloxacilin","slug":"cloxacilin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hyperbaric bupivacaine+Morphine","genericName":"Hyperbaric bupivacaine+Morphine","slug":"hyperbaric-bupivacaine-morphine","phase":"marketed","mechanism":"This combination uses bupivacaine (a local anesthetic) formulated as a hyperbaric solution with morphine (an opioid analgesic) to provide prolonged spinal anesthesia and analgesia.","indications":["Spinal anesthesia for surgical procedures","Postoperative pain management"],"catalyst":""},{"name":"Hyperbaric bupivacaine+Sufentanil","genericName":"Hyperbaric bupivacaine+Sufentanil","slug":"hyperbaric-bupivacaine-sufentanil","phase":"marketed","mechanism":"Bupivacaine blocks sodium channels in nerve fibers to produce local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation; the hyperbaric formulation increases density for spinal distribution.","indications":["Spinal anesthesia for surgical procedures","Postoperative pain management"],"catalyst":""},{"name":"Regular insulin added to TPN bag","genericName":"Regular insulin added to TPN bag","slug":"regular-insulin-added-to-tpn-bag","phase":"marketed","mechanism":"Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition.","indications":["Hyperglycemia management in patients receiving total parenteral nutrition (TPN)","Blood glucose control in critically ill patients on parenteral nutrition support"],"catalyst":""},{"name":"Roflumilast alternated days","genericName":"Roflumilast alternated days","slug":"roflumilast-alternated-days","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subcutaneous glargine insulin","genericName":"Subcutaneous glargine insulin","slug":"subcutaneous-glargine-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNZ2k1X19RZG9fQnVRUWNUc2NEZm9ZeFRjSjdlWmwzU3BTTmhzd3RZX1VmdGc1QThUYUxvXzNySVJMS0JCb3oyZGRrSVBkajRzWGJ4YlgwaHBEWFRacWE0LWtYdXVYVF9vOTAtRXc5NHlvMTFUajBMbHotWk4zZ0RNbHpFQ3dfYy1QQ3VzcENkUXBsZGQ0OFNVWUxmcU1faF85M2tXckFPY3c5dTNodXRJa0MwOUdTLXU1a0E?oc=5","date":"2025-10-29","type":"pipeline","source":"Open Access Government","summary":"3TR Project: Crossing disease borders to reshape European research - Open Access Government","headline":"3TR Project: Crossing disease borders to reshape European research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOVm8yTjgtU2ZONW9hTDdPczhUTVc1eURacWRsMHlJaXhFejduYzlZUkVfTTBNVkFIMDNiVDVWbWJ5TGtRMEhpRE5JRlo0QXBGcjd3NHdlNGt4aktYeHotbHpQMVQ1UDV6ZENWUU1ab3UyVGpUMDJLaV85QUpQVjR1bzFRYzdHMy02eWNJQUZraEU5QjdEenhJQzl1aUIxVC03ODlxbTlsSHJLaFhFTTFRMDlGT3FBWkkxX0N6YUZ5Z2E0YzhFNFFINFc5MmltTDVwc2kyaFdJTnVxaC1MbDZ6a2dJZ25mTGwteTdFc2NDLVI3ZmZYbEo2ejZIMXpGVldzcDlLaWpRTW9sSzlJazRvTzkxdENTMVZhU19n?oc=5","date":"2019-11-12","type":"pipeline","source":"rdworldonline.com","summary":"Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases - rdworldonline.com","headline":"Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Managem","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":3,"discontinued":1,"marketed":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}